Curcumin and apigenin – Novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease

Neural Regeneration Research

Volumn 10, Issue 8, 2015, Pages 1181-1185

  Venigalla, Madhuri ^a   Gyengesi, Erika ^a   Münch, Gerald ^a,b  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b WESTERN SYDNEY UNIVERSITY   (Australia)

Author keywords

Alzheimer s disease; Anti inflammatory drugs; Neuroinflammation; Plant secondary metabolites; Reactive oxygen species

Indexed keywords

AMYLOID BETA PROTEIN; APIGENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CURCUMIN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; PROSTAGLANDIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTROCYTOSIS; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); COGNITION; GLIOSIS; HUMAN; MICROGLIA; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WORKING MEMORY;

EID: 84940490884     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.162686     Document Type: Review

References (64)

1. Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39:41-47.
2. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ (2000) Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol Aging 21:39-47.
3. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN (2009) Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14:469-486.
4. Bharti AC, Donato N, Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171:3863-3871.
5. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN, Group AR (2011) Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimer’s Dement 7:402-411.
6. Castello MA, Jeppson JD, Soriano S (2014) Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease. BMC Neurol 14:169.
7. Cole GM, Teter B, Frautschy SA (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595:197-212.
8. Cox KH, Pipingas A, Scholey AB (2014) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol pii: 0269881114552744.
9. Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG (2011) Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol 49:1834-1842.
10. Eikelenboom P, Veerhuis R (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 17:673-680.
11. Fang L, Gou S, Fang X, Cheng L, Fleck C (2013) Current progresses of novel natural products and their derivatives/ analogs as anti-Alzheimer candidates: an update. Mini Rev Med Chem 13:870-887.
12. Giri RK, Selvaraj SK, Kalra VK (2003) Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol 170:5281-5294.
13. Gotz J, Eckert A, Matamales M, Ittner LM, Liu X (2011) Modes of Abeta toxicity in Alzheimer’s disease. Cell Mol Life Sci 68:3359-3375.
14. Gupta S, Afaq F, Mukhtar H (2001) Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 287:914-920.
15. Ha SK, Lee P, Park JA, Oh HR, Lee SY, Park JH, Lee EH, Ryu JH, Lee KR, Kim SY (2008) Apigenin inhibits the production of NO and PGE2 in microglia and inhibits neuronal cell death in a middle cerebral artery occlusion-induced focal ischemia mice model. Neurochem Int 52:878-886.
16. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Münch G (2007) Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias. Pharmacol Ther 113:154-164.
17. Jurenka JS (2009) Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14:141-153.
18. Kamphuis PJ, Scheltens P (2010) Can nutrients prevent or delay onset of Alzheimer’s disease? J Alzheimers Dis 20:765-775.
19. Kern JK, Geier DA, Sykes LK, Geier MR (2013) Evidence of neurodegeneration in autism spectrum disorder. Transl Neurodegener 2:17.
20. Kim J, Lee HJ, Lee KW (2010) Naturally occurring phytochemicals for the prevention of Alzheimer’s disease. J Neurochem 112:1415-1430.
21. Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, Corona W, Morse CL, Zoghbi SS, Pike VW, McMahon FJ, Turner RS, Innis RB (2013) In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain 136:2228-2238.
22. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10.
23. Latta CH, Brothers HM, Wilcock DM (2014) Neuroinflammation in Alzheimer’s disease; A source of heterogeneity and target for personalized therapy. Neuroscience doi: 10.1016/j.neuroscience.2014.09.061.
24. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D (2010) LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 7:56.
25. Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N (2006) Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol 4:21-26.
26. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK (1999) Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20:1945-1952.
27. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:8370-8377.
28. Liu R, Zhang T, Yang H, Lan X, Ying J, Du G (2011) The flavonoid apigenin protects brain neurovascular coupling against amyloid-beta(2) (5)(-)(3)(5)-induced toxicity in mice. J Alzheimers Dis 24:85-100.
29. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, Münch G (2000) Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 267:4171-4178.
30. Martin A, Boisgard R, Theze B, Van Camp N, Kuhnast B, Damont A, Kassiou M, Dolle F, Tavitian B (2010) Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia. J Cereb Blood Flow Metab 30:230-241.
31. Massoud F, Gauthier S (2010) Update on the pharmacological treatment of Alzheimer’s disease. Curr Neuropharmacol 8:69-80.
32. McKay DL, Blumberg JB (2006) A review of the bioactivity and potential health benefits of chamomile tea (Matricaria recutita L.). Phytother Res 20:519-530.
33. Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595:105-125.
34. Mishra S, Palanivelu K (2008) The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Ann Indian Acad Neurol 11:13-19.
35. Mrak RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26:349-354.
36. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P (1998) Alzheimer’s disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105:439-461.
37. Myhrstad MC, Carlsen H, Nordstrom O, Blomhoff R, Moskaug JO (2002) Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med 32:386-393.
38. Nicholas C, Batra S, Vargo MA, Voss OH, Gavrilin MA, Wewers MD, Guttridge DC, Grotewold E, Doseff AI (2007) Apigenin blocks lipopolysaccharide- induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol 179:7121-7127.
39. Panes J, Gerritsen ME, Anderson DC, Miyasaka M, Granger DN (1996) Apigenin inhibits tumor necrosis factor-induced intercellular adhesion molecule-1 upregulation in vivo. Microcirculation 3:279-286.
40. Patel A, Rees SD, Kelly MA, Bain SC, Barnett AH, Prasher A, Arshad H, Prasher VP (2014) Genetic variants conferring susceptibility to Alzheimer’s disease in the general population; do they also predispose to dementia in Down’s syndrome. BMC Res Notes 7:42.
41. Popovic M, Caballero-Bleda M, Benavente-Garcia O, Castillo J (2014) The flavonoid apigenin delays forgetting of passive avoidance conditioning in rats. J Psychopharmacol 28:498-501.
42. Prasad KN, Bondy SC (2014) Inhibition of early upstream events in prodromal Alzheimer’s disease by use of targeted antioxidants. Curr Aging Sci 7:77-90.
43. Qian L, Flood PM, Hong JS (2010) Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm 117:971-979.
44. Ray B, Lahiri DK (2009) Neuroinflammation in Alzheimer’s disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 9:434-444.
45. Retz W, Gsell W, Münch G, Rosler M, Riederer P (1998) Free radicals in Alzheimer’s disease. J Neural Transm Suppl 54:221-236.
46. Rezai-Zadeh K, Ehrhart J, Bai Y, Sanberg PR, Bickford P, Tan J, Douglas RD (2008) Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J Neuroinflammation 5:41.
47. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL (2005) A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res 2:131-136.
48. Rosenblum WI (2014) Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging 35:969-974.
49. Ross JA, Kasum CM (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19-34.
50. Shi X, Zheng Z, Li J, Xiao Z, Qi W, Zhang A, Wu Q, Fang Y (2015) Curcumin inhibits Abeta-induced microglial inflammatory responses in vitro: Involvement of ERK1/2 and p38 signaling pathways. Neurosci Lett 594:105-110.
51. Shukla S, Gupta S (2010) Apigenin: a promising molecule for cancer prevention. Pharm Res 27:962-978.
52. Singh VK, Guthikonda P (1997) Circulating cytokines in Alzheimer’s disease. J Psychiatr Res 31:657-660.
53. Smolinski AT, Pestka JJ (2003) Modulation of lipopolysaccharide-induced proinflammatory cytokine production in vitro and in vivo by the herbal constituents apigenin (chamomile), ginsenoside Rb(1) (ginseng) and parthenolide (feverfew). Food Chem Toxicol 41:1381-1390.
54. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 32:763-777.
55. Stevenson DE, Hurst RD (2007) Polyphenolic phytochemicals--just antioxidants or much more? Cell Mol Life Sci 64:2900-2916.
56. Viola H, Wasowski C, Levi de Stein M, Wolfman C, Silveira R, Dajas F, Medina JH, Paladini AC (1995) Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 61:213-216.
57. Willis LM, Freeman L, Bickford PC, Quintero EM, Umphlet CD, Moore AB, Goetzl L, Granholm AC (2010) Blueberry supplementation attenuates microglial activation in hippocampal intraocular grafts to aged hosts. Glia 58:679-690.
58. Wong A, Luth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T, Münch G (2001a) Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer’s disease. Brain Res 920:32-40.
59. Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, Schinzel R, Wiesinger H, Riederer P, Münch G (2001b) Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci 14:1961-1967.
60. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892- 5901.
61. Yin F, Giuliano AE, Van Herle AJ (1999) Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res 19:4297-4303.
62. Zhang F, Li F, Chen G (2014) Neuroprotective effect of apigenin in rats after contusive spinal cord injury. Neurol Sci 35:583-588.
63. Zhao L, Wang JL, Liu R, Li XX, Li JF, Zhang L (2013) Neuroprotective, anti-amyloidogenic and neurotrophic effects of apigenin in an Alzheimer’s disease mouse model. Molecules 18:9949-9965.
64. Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu YJ, Yu XD (2011) Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer 10:104.